PHAR Stock Overview
Manufactures and distributes medicines, and medical and veterinary preparations in Egypt and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
+ 1 more risk
Egyptian International Pharmaceutical Industries Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م39.48 |
| 52 Week High | ج.م53.49 |
| 52 Week Low | ج.م25.46 |
| Beta | 0.26 |
| 11 Month Change | 4.61% |
| 3 Month Change | -5.57% |
| 1 Year Change | 50.80% |
| 33 Year Change | -16.21% |
| 5 Year Change | -49.24% |
| Change since IPO | 606.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHAR | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | -0.3% | -0.6% | 1.4% |
| 1Y | 50.8% | 28.2% | 62.5% |
Return vs Industry: PHAR exceeded the EG Pharmaceuticals industry which returned 27.3% over the past year.
Return vs Market: PHAR underperformed the EG Market which returned 62% over the past year.
Price Volatility
| PHAR volatility | |
|---|---|
| PHAR Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in EG Market | 9.0% |
| 10% least volatile stocks in EG Market | 3.3% |
Stable Share Price: PHAR has not had significant price volatility in the past 3 months.
Volatility Over Time: PHAR's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | n/a | Ahmed Saeed Killani | www.eipico.com.eg |
Egyptian International Pharmaceutical Industries Company manufactures and distributes medicines, and medical and veterinary preparations in Egypt and internationally. It produces various dosage forms, such as spansule capsules, soft gelatin capsules, lyophilized products, gels, sprayers, and effervescent tablets, as well as antibiotics. The company also provides Covid-19 related protocol medicine, including epicehin, epizithro, cetal, dexamethasone, and cevitil.
Egyptian International Pharmaceutical Industries Company Fundamentals Summary
| PHAR fundamental statistics | |
|---|---|
| Market cap | ج.م5.87b |
| Earnings (TTM) | ج.م1.24b |
| Revenue (TTM) | ج.م5.74b |
4.7x
P/E Ratio1.0x
P/S RatioIs PHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAR income statement (TTM) | |
|---|---|
| Revenue | ج.م5.74b |
| Cost of Revenue | ج.م3.33b |
| Gross Profit | ج.م2.42b |
| Other Expenses | ج.م1.18b |
| Earnings | ج.م1.24b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.32 |
| Gross Margin | 42.09% |
| Net Profit Margin | 21.55% |
| Debt/Equity Ratio | 163.0% |
How did PHAR perform over the long term?
See historical performance and comparison